Synapse - Works

Results (275)

EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV + P) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)

Meeting Abstract

Powles, T. B.; Perez Valderrama, B.; Gupta, S.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Iyer, G.; Vulsteke, C.; Park, S. H.; Shin, S. J.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Kelly, W. K.; Danila, D. C.; Lin, C. C.; Lee, J. L.; Matsubara, N.; Ward, P. J.; Armstrong, A. J.; Pook, D. W.; Kim, M.; Dorff, T.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE

Meeting Abstract

Chi, K. N. N.; Castro, E.; Attard, G.; Smith, M. R.; Sandhu, S. K.; Efstathiou, E.; Roubaud, G.; Small, E. J. J.; Gomes, A. J. P. D. S; Rathkopf, D.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)

Meeting Abstract

Powles, T. B.; Perez Valderrama, B.; Gupta, S.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Iyer, G.; Vulsteke, C.; Park, S. H.; Shin, S. J.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)

Meeting Abstract

Sartor, O.; Castellano Gauna, D. E.; Herrmann, K.; de Bono, J. S.; Shore, N. D.; Chi, K. N. N.; Crosby, M.; Piulats Rodriguez, J. M.; Flechon, A.; Wei, X. X.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC)

Meeting Abstract

Sridhar, S.; O'Donnell, P. H.; Flaig, T. W.; Rosenberg, J. E.; Hoimes, C. J.; Milowsky, M. I.; Srinivas, S.; George, S.; McKay, R. R.; Petrylak, D. P.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Pan-cancer assessment of the impact of intronic variants on cancer development and progression

Meeting Abstract

Safonov, A.; Mehine, M.; Ceyhan-Birsoy, O.; Brown, D.; Bandlamudi, C.; Forbes, A.; Gazzo, A.; Selenica, P.; Shen, R.; Khurana, E.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial

Meeting Abstract

Gruenwald, V.; McKay, R. R.; Buchler, T.; Eto, M.; Park, S. H.; Takagi, T.; Zanetta, S.; Keizman, D.; Suarez Rodriguez, C.; Negrier, S.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

STELLAR-304: A randomized phase III study of zanzalintinib (XL092) and nivolumab in non-clear cell renal cell carcinoma (nccRCC)

Meeting Abstract

Pal, S. K.; Powles, T. B.; Kanesvaran, R.; Lee, C. H.; Liu, M.; Wang, Z.; Bhatt, A.; Patel, P.; Suarez Rodriguez, C.
Annals of Oncology (2023)

Fulltext@MSK | Save

Prognostic value of neutrophil-to-lymphocyte ratio and lymphopenia in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with [177Lu]Lu-PSMA-617: VISION post hoc analysis

Meeting Abstract

Wei, X. X.; Chi, K. N. N.; de Bono, J. S.; Fizazi, K.; Krause, B.; Herrmann, K.; Rahbar, K.; Tagawa, S. T.; Morris, M. J.; Meisel, A.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save